{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["5(1)"],"submitter":["Knoerl R"],"funding":["mittelman integrative oncology family fund"],"pubmed_abstract":["Background
Timely detection of chemotherapy-induced peripheral neuropathy (CIPN) is critical to effectively tailor chemotherapy dose levels and offer supportive care. The purpose of this secondary analysis was to determine the reliability and validity of the two Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™) numbness and tingling severity and interference items to screen for CIPN in patients receiving taxanes, platinums, or proteasome inhibitors.Methods
Participants (N = 142) completed the two PRO-CTCAE items, a 0-10 numerical rating scale of worst CIPN pain intensity, and the Quality of Life Questionnaire-CIPN20 (QLQ-CIPN20) prior to three clinical visits (T1, T2, T3) during neurotoxic chemotherapy. Participants complet"],"journal":["Journal of patient-reported outcomes"],"pagination":["101"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8473487"],"repository":["biostudies-literature"],"pubmed_title":["Measurement properties of brief neuropathy screening items in cancer patients receiving taxanes, platinums, or proteasome inhibitors."],"pmcid":["PMC8473487"],"pubmed_authors":["Knoerl R","Mitchell SA","McCleary N","Salehi E","Mazzola E","Hong F","Berry DL","Reyes K","Ligibel JA"],"additional_accession":[]},"is_claimable":false,"name":"Measurement properties of brief neuropathy screening items in cancer patients receiving taxanes, platinums, or proteasome inhibitors.","description":"Background
Timely detection of chemotherapy-induced peripheral neuropathy (CIPN) is critical to effectively tailor chemotherapy dose levels and offer supportive care. The purpose of this secondary analysis was to determine the reliability and validity of the two Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™) numbness and tingling severity and interference items to screen for CIPN in patients receiving taxanes, platinums, or proteasome inhibitors.Methods
Participants (N = 142) completed the two PRO-CTCAE items, a 0-10 numerical rating scale of worst CIPN pain intensity, and the Quality of Life Questionnaire-CIPN20 (QLQ-CIPN20) prior to three clinical visits (T1, T2, T3) during neurotoxic chemotherapy. Participants complet","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Sep","modification":"2025-04-04T03:40:11.853Z","creation":"2022-02-11T11:59:56.014Z"},"accession":"S-EPMC8473487","cross_references":{"pubmed":["34568984"],"doi":["10.1186/s41687-021-00377-z"]}}